Corticotrophin secreetion capacity after long-term corticotrophin treatment in multiple sclerosis.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000324:Adrenocorticotropic Hormone / Q000378:metabolism* / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008797:Metyrapone; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010901:Pituitary Function Tests; D014642:Vanilmandelic Acid / Q000652:urine; D014667:Vasopressins
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D014667:Vasopressins; D014642:Vanilmandelic Acid; D000324:Adrenocorticotropic Hormone; D008797:Metyrapone